NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Drugs Context
Главные авторы: Cawston, Helene, Bourhis, Francois, Eriksson, Jennifer, Ruffo, Pierfrancesco, D’Agostino, Paolo, Turini, Marco, Schwartzberg, Lee, McGuire, Alistair
Формат: Artigo
Язык:Inglês
Опубликовано: Just Medical Media Limited 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378057/
https://ncbi.nlm.nih.gov/pubmed/28392826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212298
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы